Skip to content

Exeltis uses a technology called “cookies” with the purpose of facilitating Users’ navigation and providing information during their use of our Website. This Cookies Policy supplements our Privacy Policy and provides more information regarding the specific types of cookies that we use.

1. What are cookies?

A cookie is a file that may be stored on your computer or mobile device with the purpose of storing data that may be updated and recovered by the company responsible for its installation, including Exeltis and our third-party vendors. This may include pages you have visited, choices you have made from menus, any specific information you have entered forms and the time and date of your visit. Depending on their use and content, cookies may be used to recognize the User.

2. What types of cookies do we use and for what purpose?

Exeltis uses first-party and third-party cookies. Third-party cookies are those that are managed by service providers external to Exeltis. Our Website uses the following cookie types:

  1. Technical and Personalization cookies are required to allow the User to use different options or services offered in the Websites. If these cookies are disabled, you will not be able to properly receive our contents or services.
    1. Login cookies designed to collect and store data while the User accesses the Website. They are usually used in the context of the provision of a service requested by the User on a single occasion.
    2. Permanent cookies or persistent cookie are data files capable of providing Services with user preferences, settings and information for future visits. Persistent cookies provide convenient and rapid access to familiar objects, which enhances the user experience.
  2. Analytics cookies, these cookies are used to tracking and analysing user’s behaviour. If these cookies are disabled, the Websites will continue functioning, notwithstanding the information collected by these cookies allows us to improve our Websites.

Cookie Type: TECHNICAL

Description: These cookies are essential to improve your navigation experience and the proper functioning of our Websites.

The cookies are essential for remembering previous settings so you do not have to reconfigure them every time you visit us.

Categories of Third Parties:

Third-Party Services:

Cookie Type: LOG

Description: These cookies are created when you register or log in into our Websites.

Categories of Third Parties:

Third-Party Services:

Cookie Type: ANALYTICS

Description: These cookies collect information related to your navigation experience in our Website. We are able to quantify how many visitors reach the Website or the most viewed contents.

Categories of Third Parties:

Third-Party Services:

Cookie Type: SOCIAL

Description: Each social network uses its own cookies so that you can click on “Like” or “Share” buttons. Categories of

Third Parties:

Third-Party Services:

Cookie Type: BEHAVIOURAL ADVERTISING

Description: They allow the management of Services advertising spaces. They store information on the behaviour of users obtained through continuous observation of their browsing habits, which allows the development of a specific profile to show advertising according to it.

Categories of Third Parties:

Third-Party Services:

CookieTypeDurationDescription
_fbp3 monthsFacebook sets this cookie to display advertisements when either on Facebook or on a digital platform powered by Facebook advertising after visiting the website.
_ga1 year 1 month 4 daysGoogle Analytics sets this cookie to calculate visitor, session and campaign data and track site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognise unique visitors.
_ga_*1 year 1 month 4 daysGoogle Analytics sets this cookie to store and count page views.
_gcl_au3 monthsGoogle Tag Manager sets the cookie to experiment advertisement efficiency of websites using their services.
_rdt_uuid3 monthsReddit sets this cookie to build a profile of your interests and show you relevant ads.
_tt_enable_cookie1 year 24 daysTiktok set this cookie to collect data about behaviour and activities on the website and to measure the effectiveness of the advertising.
_ttp1 year 24 daysTikTok set this cookie to track and improve the performance of advertising campaigns, as well as to personalise the user experience.
CDIUSER1 year 1 month 4 daysThis cookie is set by the provider Deepintent. This cookie is used for serving the visitor with relevant content and advertisements. This is done by third party advertisement hubs which provide real time bidding for advertisers.
cookielawinfo-checkbox-advertisement1 yearSet by the GDPR Cookie Consent plugin, this cookie records the user consent for the cookies in the "Advertisement" category.
cookielawinfo-checkbox-analytics011 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional011 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary011 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others011 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance011 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
CookieLawInfoConsent1 yearCookieYes sets this cookie to record the default button state of the corresponding category and the status of CCPA. It works only in coordination with the primary cookie.
INGRESSCOOKIEsessionThis cookie is used for load balancing and session stickiness. This technical session identifier is required for some website features.
sa-user-id1 yearStackAdapt sets this cookie as a third party advertising cookie to record information about a user's website activity, such as the pages visited and the locations viewed, to enable us to provide users with interest-based content and personalised advertisements on external websites.
sa-user-id-v21 yearStackAdapt sets this cookie as a third party advertising cookie to record information about a user's website activity, such as the pages visited and the locations viewed, to enable us to provide users with interest-based content and personalised advertisements on external websites.
sa-user-id-v31 yearDescription is currently not available.
viewed_cookie_policy011 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
VP1 yearDescription is currently not available.

4. Data Protection and Cookies

Exeltis, uses the cookies listed above to collect, use, and disclose personal data. For more information relating to the types of personal data collected, and any rights you may have in relation to such cookie use, please refer to our Privacy Policy.

5. How may I disable and block cookies?

At any time, you may be able to disable or control cookies by following instructions in your browser settings. Please note that if you do so, you will be able to continue using our Website, although some functionality may be limited or not work as intended.

For information related to opt out options provided by Google Analytics, please visit the following link: https://tools.google.com/dlpage/gaoptout?hl=es.

In order to obtain more information related to the way of adjusting the settings of each browser, please visit the following links:

Internet Explorer:
http://support.microsoft.com/kb/196955
http://support.microsoft.com/kb/283185
http://www.allaboutcookies.org/manage-Cookies/internet-explorer7- plus.html
http://www.allaboutcookies.org/manage-Cookies/internet-explorer8- plus.html
http://windows.microsoft.com/is-IS/windows7/How-to-manage-Cookies-in-Internet-explorer-9

Firefox:
http://support.mozilla.org/en-US/kb/cookies

Chrome:
http://support.google.com/chrome/bin/answer.py?hl=en&answer=95647

Safari:
http://support.apple.com/kb/PH5042

iOS:
http://support.apple.com/kb/HT1677

Effective date of the Policy: July the 10th, 2024

Slynd® Important Safety Information


Slynd does not protect against HIV infection (AIDS) and other sexually transmitted diseases (STDs).
What is Slynd?
SLYND (drospirenone) tablets are a progestin, indicated for females of reproductive potential to prevent pregnancy.
SLYND is contraindicated in females with renal impairment, adrenal insufficiency, a presence or history of cervical cancer or progestin sensitive cancers, liver tumors (benign or malignant) or hepatic impairment, and undiagnosed abnormal uterine bleeding.

Slynd® Important Safety Information


Slynd does not protect against HIV infection (AIDS) and other sexually transmitted diseases (STDs).

Indication

SLYND (drospirenone) tablets are a progestin, indicated for females of reproductive potential to prevent pregnancy.

Contraindications

SLYND is contraindicated in females with renal impairment, adrenal insufficiency, a presence or history of cervical cancer or progestin sensitive cancers, liver tumors (benign or malignant) or hepatic impairment, and undiagnosed abnormal uterine bleeding.

Warnings and Precautions

Hyperkalemia: SLYND has anti-mineralocorticoid activity, including the potential for hyperkalemia in high-risk females. Check serum potassium levels prior to starting treatment and during the first treatment cycle in females receiving daily, long-term treatment for chronic conditions or diseases with medications that may increase serum potassium concentration. Consider monitoring serum potassium concentration in females at increased risk for hyperkalemia i.e., those females who take a strong CYP3A4 inhibitor long-term and concomitantly with SLYND. Monitor females taking SLYND who later develop conditions and/or begin medication that put them at an increased risk for hyperkalemia.

Thromboembolic Disorders: Epidemiological studies have not indicated an association between progestin-only preparations and an increased risk of myocardial infarction, cerebral thromboembolism, or venous thromboembolism. Consider the increased risk of thromboembolism inherent in the postpartum period and in females with a history of thromboembolism. Discontinue SLYND if a thromboembolic event occurs and consider discontinuing SLYND in case of prolonged immobilization due to surgery or illness.

Bone Loss: Treatment with SLYND leads to decreased estradiol serum levels. It is unknown if this may cause a clinically relevant loss of bone mineral density.

Liver Disease: Discontinue SLYND if jaundice or acute or chronic disturbances of liver function develop. Do not resume use until markers of liver function return to normal and SLYND causation has been excluded.

Ectopic Pregnancy: Be alert to the possibility of ectopic pregnancy in females who become pregnant or complain of lower abdominal pain while on SLYND.

Risk of Hyperglycemia in Patients with Diabetes: Females with diabetes may be at greater risk of hyperglycemia and may require additional medication adjustments or monitoring. Progestins, including SLYND, may decrease insulin sensitivity.

Bleeding Irregularities and Amenorrhea: Females may experience unscheduled (breakthrough or intracyclic) bleeding and spoVng, especially during the first three months of use. If bleeding persists, occurs aWer previously regular cycles, or if scheduled bleeding does not occur, evaluate for possible causes such as pregnancy or malignancy.

Depression: Carefully observe females with a history of depression and discontinue SLYND if depression recurs to a serious degree. Data on the association of progestin-only contraceptive products with onset of depression and exacerbation of depression are limited.

The most common adverse reactions (>1%) are: acne, metrorrhagia, headache, breast pain, weight increased, dysmenorrhea, nausea, vaginal hemorrhage, decreased libido, breast tenderness, irregular menstruation.

Drug Interactions Drugs or herbal products that induce certain enzymes (for example, CYP3A4) may decrease the effectiveness of SLYND® or increase breakthrough bleeding. Counsel patients to use a back- up or alternative non-hormonal method of contraception when enzyme inducers are used with SLYND and to continue back-up non-hormonal contraception for 28 days aWer discontinuing the enzyme inducer. Drugs or products that inhibit CYPtiA4 may increase SLYND systemic exposure.

Are you a healthcare professional?

You are entering a page reserved for U.S. healthcare professionals only. By clicking on “Yes” below, you are confirming that you are a healthcare professional and wish to enter this page.

Yes, I am

If you are a Canadian healthcare professional, please visit slynd.ca

Go to slynd.ca

You're about to continue to our partner site

You are now leaving Slynd.com to visit a website that is not owned or operated by Exeltis USA, Inc. Links to outside sites are provided as a resource to our visitors and do not imply an endorsement or recommendation of a particular healthcare provide by Exeltis, nor an endorsement of any Exeltis product by any healthcare provider.

Exeltis accepts no responsibility or liability for the content or services of other websites. All prescription decisions are at the sole discretion of the healthcare provider based on each patient’s individual needs.

Proceed to Nurx